

**Technology Available for Industry-Academia Collaboration or Technology
Licensing. “Taiwan Polycystic Kidney Disease”**

Date: 2023.07.10

1. Title:
NHRI technology, “Taiwan Polycystic Kidney Disease” (abbreviated as “**The Technology**”) available for industry-academia collaboration or technology licensing.

2. Description:
Autosomal Dominant polycystic kidney disease (ADPKD) is the most common inherited adult kidney disease. Although ADPKD is primarily caused by *PKD1* and *PKD2*, the identification of several novel causative genes in recent years has revealed more complex genetic heterogeneity than previously thought. To study the disease-causing mutations of ADPKD, a total of 920 families were collected and their diagnoses were established via clinical and image studies by Taiwan PKD Consortium investigators. Disease-causing mutations were identified in 634 families (68.9%) by detection of 364 *PKD1*, 239 *PKD2*, 18 *PKHD1*, 7 *GANAB*, and 6 *ALG8* pathogenic variants. 162 families (17.6%) had likely causative but non-diagnostic variants of unknown significance (VUS). A single *PKD2* p.Arg803* mutation was found in 17.8% (164/920) of the cohort in Taiwan.

We are soliciting companies for industry- academia collaboration related to ethnic genes in Taiwan cohort.

3. Potential collaboration partner qualifications:

- (1) be incorporated and approved by law and does not have any record of misconduct or conviction for any offense
- (2) better to have related experience and skills for developing **The Technology**
- (3) better to have experience of international collaboration and clinical trial
- (4) better to be ready to invest or be able to raise the funds

4. Registration :
Please contact to Ms. Wan-Ping Hsieh (Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan, R.O.C., Tel: +88637-246166 # 33227, E-mail: wanping@nhri.edu.tw).

5. Other:

- (1) If **The Technology** has been exclusively licensed, this announcement will automatically be invalid.
- (2) NHRI retains the right to modify and terminate this announcement.
- (3) For detailed status of **The Technology**, please contact the case officer.

Attachments:

I: Announcement

II: Technology Transfer Vendor Qualification Form

III: Industry-Academia Collaboration Proposal